Real-World data on caplacizumab for rare blood disorder
NCT ID NCT04985318
First seen May 05, 2026 · Last updated May 07, 2026 · Updated 1 time
Summary
This study reviews medical records of 350 adults with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab. Researchers want to see how doctors decide to use the drug, how well it works outside of clinical trials, and what factors predict complications. The goal is to create better treatment plans that improve outcomes and lower costs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Cologne
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.